These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15997922)

  • 1. Nuclear localisation of glutathione S-transferase pi is an evaluation factor for drug resistance in gynaecological cancers.
    Soh Y; Goto S; Kitajima M; Moriyama S; Kotera K; Nakayama T; Nakajima H; Kondo T; Ishimaru T
    Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):264-70. PubMed ID: 15997922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi.
    Goto S; Ihara Y; Urata Y; Izumi S; Abe K; Koji T; Kondo T
    FASEB J; 2001 Dec; 15(14):2702-14. PubMed ID: 11726546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of glutathion-S transferase pi as a prognostic factor in epithelial ovarian carcinoma.
    Saip P; Tuzlali S; Demir K; Sakar B; Yavuz E; Berkman S; Bengisu E; Topuz E
    Eur J Gynaecol Oncol; 2005; 26(1):90-4. PubMed ID: 15755010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.
    Mayr D; Pannekamp U; Baretton GB; Gropp M; Meier W; Flens MJ; Scheper R; Diebold J
    Pathol Res Pract; 2000; 196(7):469-75. PubMed ID: 10926324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs.
    Goto S; Kamada K; Soh Y; Ihara Y; Kondo T
    Jpn J Cancer Res; 2002 Sep; 93(9):1047-56. PubMed ID: 12359059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells.
    Goto S; Iida T; Cho S; Oka M; Kohno S; Kondo T
    Free Radic Res; 1999 Dec; 31(6):549-58. PubMed ID: 10630679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear glutathione S-transferase pi prevents apoptosis by reducing the oxidative stress-induced formation of exocyclic DNA products.
    Kamada K; Goto S; Okunaga T; Ihara Y; Tsuji K; Kawai Y; Uchida K; Osawa T; Matsuo T; Nagata I; Kondo T
    Free Radic Biol Med; 2004 Dec; 37(11):1875-84. PubMed ID: 15528046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutathion S transferase pi indicates chemotherapy resistance in breast cancer.
    Su F; Hu X; Jia W; Gong C; Song E; Hamar P
    J Surg Res; 2003 Jul; 113(1):102-8. PubMed ID: 12943817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.
    Koshiyama M; Fujii H; Kinezaki M; Yoshida M
    Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
    Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.
    Hsu CH; Chen CL; Hong RL; Chen KL; Lin JF; Cheng AL
    Oncology; 2002; 62(4):305-12. PubMed ID: 12138237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.
    Surowiak P; Materna V; Kaplenko I; Spaczyński M; Dietel M; Lage H; Zabel M
    Virchows Arch; 2005 Sep; 447(3):626-33. PubMed ID: 15968547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutathione S-transferase pi immunostaining of cisplatin-resistant ovarian cancer cells in ascites.
    Kase H; Kodama S; Nagai E; Tanaka K
    Acta Cytol; 1998; 42(6):1397-402. PubMed ID: 9850649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutathione S-transferase expression in benign and malignant ovarian tumours.
    Green JA; Robertson LJ; Clark AH
    Br J Cancer; 1993 Aug; 68(2):235-9. PubMed ID: 8347477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy.
    Hamada S; Kamada M; Furumoto H; Hirao T; Aono T
    Gynecol Oncol; 1994 Mar; 52(3):313-9. PubMed ID: 8157188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of P-glycoprotein and glutathione S-transferase-pi as chemo-resistant indicators in ovarian cancers].
    Zhang F; Qi L; Chen H
    Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):313-6. PubMed ID: 11783115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutathione-S-transferase activity and isoenzyme levels measured by two methods in ovarian cancer, and their value as markers of disease outcome.
    Wrigley EC; McGown AT; Buckley H; Hall A; Crowther D
    Br J Cancer; 1996 Mar; 73(6):763-9. PubMed ID: 8611377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
    Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
    Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer.
    Tanner B; Hengstler JG; Dietrich B; Henrich M; Steinberg P; Weikel W; Meinert R; Kaina B; Oesch F; Knapstein PG
    Gynecol Oncol; 1997 Apr; 65(1):54-62. PubMed ID: 9103391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.